Treatment Outcome of Stereotactic Body Radiotherapy for Patients with Lung Tumors: A Retrospective Study at Chulabhorn Hospital
Pornwaree Trirussapanich MD1, Poompis Pattaranutraporn MD1, Thong Chotchutipan MD1, Danupon Nantajit PhD1, Ruja Sricharoen MD1, Sunanta Rojwatkarnjana MD1, Kanyanee Laebua MD1, Sasikarn Chamchod MD1,2
Affiliation : 1 Department of Radiation Oncology, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand 2 Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand
Background : Stereotactic body radiation therapy [SBRT] is a treatment option in several malignant diseases.
Objective : To assess the treatment outcome of SBRT in lung tumors in terms of response rates, local control, overall survival,
and prognostic factors associated with response rate.
Materials and Methods: Twenty-one patients (32 lesions) with early-stage non-small cell lung cancer [NSCLC] or
oligometastatic lung disease who received SBRT between January 2012 and March 2016 were included in this retrospective
study. Overall survival and local control rate were calculated using the Kaplan-Meier method. Prognostic factors for response
rate, including equivalent sphere diameter, tumor volume, biologically effective dose, and tumor type and location, were
analyzed using Fisher’s exact test.
Results : Median follow-up was 16.1 months; 59.4% of patients had complete response, 28.1% had partial response, and
only 3.1% had progressive disease. Local control at 1, 2, and 3 years was 94.1%, 87.4%, and 87.4%, respectively. Overall
survival at 1, 3, and 5 years was 90.2%, 90.2%, and 67.7%, respectively. In univariate analysis for response rate, tumor type
(primary or metastatic) was the only significant factor.
Conclusion : SBRT in early-stage NSCLC and oligometastatic lung tumors produces promising outcomes in terms of
response rate and local disease control.
Keywords : Stereotactic body radiation therapy [SBRT]; Treatment outcome; Early-stage NSCLCs; Oligometastatic diseases
